As the PFS of GCT patients who are not eligible for or relapsed after HDCT and do not have further curative treatment options is reported to be ~10% at six months25,26, the PFS of 42% at six months achieved with CLDN6 CAR-T cells in the seven GCT patients is compelling. Here, CLDN6 is linked to granular cell tumor.